Canine CD20 Full Length Protein (VLP)

Application

1. Immunization
2. Cell based assay (FACS or functional assay)
3. Screening (ELISA)

Synonyms

MS4A1, CD20, MS4A-1

Source

Canine CD20 Full Length Protein (VLP) (CD0-C52P3) is expressed from human 293 cells (HEK293). It contains AA Met 1 - Pro 297 (Accession # Q3C2E2-1).

Predicted N-terminus: Met 1

Molecular Characterization

*The isotype control of empty/mock VLP (Cat. No. VLP-N5213) is sold separately and not included in protein, you can follow the link for product information.

1. Structure

   

   Virus-like particles (VLPs) are protein particles that mimic the shape of viruses but lack a viral genome, and incorporating transmembrane proteins on the external surface.

2. Synthesis Process

   

   Envelope virus-like particles (eVLPs) are produced by co-expressing target membrane proteins with viral structural proteins in mammalian cells, enabling native embedding of membrane proteins into the lipid bilayer during VLP budding. This approach preserves authentic conformation, post-translational modifications, and orientation, while creating a completely detergent-free environment with repetitive multivalent display and strong immunogenicity making them ideal for immunization, binding assays in antibody discovery and screening (ELISA), and cell-based assays such as FACS, etc.

Formulation

The VLPs are highly immunogenic, so the immunization strategy should be optimized (antigen dose, regimen and adjuvant).

Supplied as 0.2 μm filtered solution in PBS, Arginine, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

Shipping

This product is supplied and shipped with dry ice, please inquire the shipping cost.

Storage

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

1. The product MUST be stored at -70°C or lower upon receipt;
2. -70°C for 12 months under sterile conditions.

ACRO Quality Management System

1. QMS(ISO, GMP)
2. Quality Advantages
3. Quality Control Process